Chester County News and Community Website
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that the first patient has been dosed in the Phase 1/2 GRECO-1 clinical trial of GC4711 in combination with stereotactic body …
Read More
EXTON, PA — Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved …
Read More
DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE is presenting a poster describing data from the Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a …
Read More
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced that clinical data from its NeuroStar Outcomes Registry, which suggests NeuroStar Advanced Therapy be evaluated as a first-line treatment for Major Depressive …
Read More
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, announced that it has expanded its …
Read More
BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS) announced the publication of peer-reviewed data demonstrating the ability of its lead candidate, ANVS401, also known as Posiphen, to improve axonal …
Read More
MALVERN, PA — TELA Bio, Inc. announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.
Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that positive results from the two pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]) studies evaluating the safety and …
Read More
EXTON, PA — Melior Pharmaceuticals (Melior) has been awarded a grant from the Commonwealth of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program, which is designed to support rapid advancement …
Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) announced that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion …
Read More